Intra-Cellular Therapies (ITCI) Appoints Sanjeev Narula as CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital
August 8, 2024 6:23 AM EDTRBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $106.00 (from $107.00) while maintaining a Outperform rating.
The analyst comments "Caplyta continues to grow in its approved indications and with MDD filings and data presentations on track... More
